Use of @entity927 in XXXX surgery.

@entity1 @entity190 @entity928 @entity927 @entity91
BACKGROUND: Intraoperative @entity927 ( @entity928 ) administration has been used to abate @entity190 in a variety of surgical procedures. Several recent studies have supported its efficacy in reducing transfusion requirements in pediatric cranial vault reconstruction (CVR). OBJECTIVE: To conduct a retrospective chart review to determine whether a significant reduction in packed red blood cell (PRBC) and fresh frozen plasma (FFP) transfusions exists when @entity928 is used. METHODS: A retrospective cohort study of 28 @entity1 who underwent CVR for @entity91 was performed. Transfusion requirements for 14 @entity1 who did not receive @entity928 were compared with 14 @entity1 who did. Predictors of increased blood product transfusion were also studied. RESULTS: Total volume of PRBC transfusion was reduced by 50% with the use of @entity928 (P=0.004) with a 34% reduction in intraoperative PRBC transfusion (P=0.017) and a 67% reduction in postoperative PRBC transfusion (P<0.001). Total volume of FFP transfusion was reduced by 46% (P=0.002) and postoperative FFP transfusion was reduced by 100% (P=0.001). The use of @entity928 was associated with a lower total volume of PRBC (P=0.003) and FFP (P=0.003) transfusions. Older @entity1 age was associated with lower total volume of PRBC transfused (P=0.046 and P=0.002), but not with FFP (P=0.183 and P=0.099) transfusion volumes. Increasing @entity1 weight was associated with lower PRBC (P=0.010 and P=0.020) and FFP (P=0.045 and P=0.016) transfusion volumes. CONCLUSION: @entity928 decreased blood product transfusion requirements in @entity1 undergoing CVR for @entity91 , and should be a routine part of the strategy to reduce @entity190 in these procedures.
